[Feasibility of FP Therapy in Outpatient Setting for Inoperable Recurrent Esophageal Cancer].

With the emergence of immune checkpoint inhibitors(ICIs)in recent years, the treatment outcomes for unresectable recurrent esophageal cancer have improved markedly. In 5-FU+cisplatin(FP)first-line therapy, 5-FU administration takes 5 days and generally requires hospitalization. However, frequent hospitalization for treatment is a crucial issue that must be resolved in terms of time investment and optimal use of hospital resources. Here, we evaluated the safety and potential adverse effects of the administration of FP therapy in an outpatient setting. After central venous ports were placed in 5 patients, cisplatin was administered using a short hydration method and 5-FU was infused for 120 hours using an infusion pump. No crucial adverse events or major pump-related problems occurred, suggesting the feasibility of this treatment in an outpatient setting. However, the duration of 5-FU administration via the pump varied more than the expected deviation (10%, 12 hours), indicating that the issues require further consideration.